← Back to Search

MRI for Lupus

N/A
Recruiting
Led By Rebecca Krimins, DVM, MS
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female adults over the age of 18 who have been diagnosed with SLE and are able to undergo a kidney MRI.
Be older than 18 years old
Must not have
Patient who has undergone a renal transplant.
Patient receiving renal dialysis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six months
Awards & highlights

Summary

This trial aims to see if a non-invasive kidney MRI can help diagnose lupus kidney disease in patients with lupus. Participants will have a kidney MRI lasting 30-60 minutes and may have

Who is the study for?
This trial is for individuals with systemic lupus erythematosus (SLE) who may have kidney inflammation known as lupus nephritis. Details on specific inclusion and exclusion criteria are not provided, but typically participants would need to meet certain health standards.
What is being tested?
The study is testing the use of non-invasive kidney MRI scans to diagnose lupus nephritis in SLE patients. Participants will undergo one or more MRI scans over six months to assess this diagnostic method.
What are the potential side effects?
MRI is a safe procedure with few side effects; however, some people might experience discomfort from lying still during the scan or claustrophobia inside the MRI machine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18, diagnosed with SLE, and can have a kidney MRI.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a kidney transplant.
Select...
I am currently on kidney dialysis.
Select...
I do not have any conditions or devices that prevent me from having an MRI.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Presence of atrophy
Presence of fibrosis
Presence of inflammation
Secondary outcome measures
Atrophy in the kidneys will be correlated to UPCR (Urine Protein Creatinine Ratio)
Atrophy will be correlated with kidney biopsy classes
Fibrosis in the kidneys will be correlated to UPCR (Urine Protein Creatinine Ratio)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRIExperimental Treatment1 Intervention
A participant will undergo a MRI (1-4).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~1620

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,307 Previous Clinical Trials
14,861,894 Total Patients Enrolled
Janssen Scientific Affairs, LLCIndustry Sponsor
161 Previous Clinical Trials
579,926 Total Patients Enrolled
1 Trials studying Lupus Nephritis
160 Patients Enrolled for Lupus Nephritis
Rebecca Krimins, DVM, MSPrincipal InvestigatorJohns Hopkins School of Medicine
~10 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top